A year later, a phase II study was conducted in order to evaluate the activity of gemcitabine as a radiosensitizer for newly diagnosed GBM; this trial showed that concomitant radiotherapy-gemcitabine is actually active both in tumors with methylated and unmethylated MGMT promoter and it is well tolerated [42,43]. The gene discussed is MGMT; the disease is glioblastoma.